Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Trastuzumab and pertuzumab are targeted therapies for Human Epidermal growth factor Receptor 2 (HER2)-positive cancers.
• Combination therapy demonstrates enhanced anti-tumor activity, but downstream signaling mechanisms remain incompletely understood.

Purpose of the Study:

• To comprehensively investigate the molecular signaling pathways affected by trastuzumab, pertuzumab, and their combination in vivo.
• To identify distinct and common downstream effects of these HER2-targeted agents.

Main Methods:

• Transcriptome profiling was conducted on human ovarian cancer models following 4 days of treatment with trastuzumab, pertuzumab, or combination therapy.
• Signaling pathway analysis was validated at the protein level in primary ovarian xenografts over a time series.

Main Results:

• Combination therapy induced a greater number and variety of gene expression changes compared to monotherapy.
• Increased levels of cyclin-dependent kinase inhibitors (p21, p27) were observed with combination treatment.
• Distinct expression patterns of proliferation, apoptosis, and cell-cycle markers suggest heterogeneity in ovarian cancer response.

Conclusions:

• This study provides the first comprehensive analysis of the in vivo molecular response to trastuzumab, pertuzumab, and combination therapy.
• Distinct downstream signaling effects were observed for monotherapy versus combination therapy, indicating involvement of complementary pathways.
• The heterogeneity of response underscores the need for predictive biomarkers in HER2-targeted ovarian cancer treatment.